A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells

被引：28
|
作者：
Kanamori, Y
Kigawa, J
Minagawa, Y
Irie, T
Oishi, T
Shimada, M
Takahashi, M
Nakamura, T
Sato, K
Terakawa, N
机构：
[1] Tottori Univ, Sch Med, Dept Obstet & Gynaecol, Yonago, Tottori 683, Japan
[2] Tottori Univ, Sch Med, Dept Biol Mol, Yonago, Tottori 683, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷 / 11期
关键词：
ovarian cancer; CDDP; p53 gene transfer; recombinant adenovirus;
D O I：
10.1016/S0959-8049(98)00199-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) was developed and the combination effect of p53 gene transfer and cis-diamminedichloroplatinum (II) (CDDP) was examined in an ovarian cancer cell line, SK-OV-3, with deletion of the p53 gene. AxCAp53 showed a high efficiency of gene transduction and increased sensitivity to CDDP in the SK-OV-3 cells. It was found that the sensitivity of the cells to CDDP correlated with the amount of infectious units of virus per cell of AxCAp53 which correlated with p53 protein expression. The results suggest that the combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP-resistant ovarian cancer. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：1802 / 1806
页数：5
相关论文
共 50 条
  • [31] Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
    Harris, MP
    Sutjipto, S
    Wills, KN
    Hancock, W
    Cornell, D
    Johnson, DE
    Gregory, RJ
    Shepard, HM
    Maneval, DC
    CANCER GENE THERAPY, 1996, 3 (02) : 121 - 130
  • [32] Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells
    M Cascalló
    E Mercadé
    G Capellà
    F Lluís
    C Fillat
    A M Gómez-Foix
    A Mazo
    Cancer Gene Therapy, 1999, 6 : 428 - 436
  • [33] Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity
    Sah, NK
    Munshi, A
    Nishikawa, T
    Mukhopadhyay, T
    Roth, JA
    Meyn, RE
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (11) : 1223 - 1231
  • [34] Gene therapy of malignant gliomas: Adenovirus-mediated wild-type p53 expression induces widespread apoptosis of human glioma cells independently of endogenous p53 status
    Li, HW
    Lochmuller, H
    Seth, P
    Karpati, G
    Nalbantoglu, J
    NEUROLOGY, 1997, 48 (03) : 1026 - 1026
  • [35] Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells
    Cascalló, M
    Mercadé, E
    Capellà, G
    Lluís, F
    Fillat, C
    Gómez-Foix, AM
    Mazo, A
    CANCER GENE THERAPY, 1999, 6 (05) : 428 - 436
  • [36] Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum(II)
    Husain, A
    Rosales, N
    Schwartz, GK
    Spriggs, DR
    GYNECOLOGIC ONCOLOGY, 1998, 70 (01) : 17 - 22
  • [37] Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells
    Buttgereit, P
    Schakowski, F
    Märten, A
    Brand, K
    Renoth, S
    Ziske, C
    Schöttker, B
    Ebert, O
    Schroers, R
    Schmidt-Wolf, IGH
    CANCER GENE THERAPY, 2001, 8 (06) : 430 - 439
  • [38] Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53
    Jin, X
    Burke, W
    Rothman, K
    Lin, J
    ANTICANCER RESEARCH, 2002, 22 (2A) : 659 - 664
  • [39] p53 adenovirus-mediated gene therapy for human bladder cancer
    Pagliaro, LC
    Keyhani, A
    Liu, B
    Perotte, P
    Wood, M
    Dinney, C
    Wilson, D
    CANCER GENE THERAPY, 1998, 5 (06) : S23 - S24
  • [40] ADENOVIRUS-MEDIATED GENE-TRANSFER OF WILD-TYPE P53 RESULTS IN MELANOMA CELL APOPTOSIS IN-VITRO AND IN-VIVO
    CIRIELLI, C
    RICCIONI, T
    YANG, CL
    PILI, R
    GLOE, T
    CHANG, J
    INYAKU, K
    PASSANITI, A
    CAPOGROSSI, MC
    INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (05) : 673 - 679
12345